Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin effect on drug metabolism in type 2 diabetes
NCT04504045Phase 1Terminated
- Sponsor
- University of Southern Denmark
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by University of Southern Denmark. Primary endpoint: Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 3. Started Sep 2020; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04504045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504045.